Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Horizon Therapeutics
(NQ:
HZNP
)
110.63
-0.62 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 27, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,600,140
Open
111.20
Bid (Size)
110.40 (3)
Ask (Size)
110.95 (12)
Prev. Close
111.25
Today's Range
110.62 - 111.34
52wk Range
57.84 - 117.49
Shares Outstanding
226,621,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Rule 15 (c) Announcement – Horizon Therapeutics plc
January 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
January 25, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Performance
YTD
-2.53%
-2.53%
1 Month
-2.55%
-2.55%
3 Month
+73.32%
+73.32%
6 Month
+33.34%
+33.34%
1 Year
+26.65%
+26.65%
More News
Read More
Rule 17 (b) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 17 (a) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder
January 18, 2023
Via
Benzinga
$1000 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth This Much Today
January 10, 2023
Via
Benzinga
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
December 27, 2022
Via
Benzinga
A Bullish Sign Appears On Horizon Therapeutics's Chart
December 27, 2022
Via
Benzinga
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
January 18, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 2.12 Announcement – Horizon Therapeutics plc
January 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
3 Biotech Companies to Watch in 2023
January 06, 2023
Via
InvestorPlace
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
Via
InvestorPlace
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
5 Most Expensive Health Care Stocks You Should Worry About
January 03, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 29, 2022
Via
Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
December 24, 2022
Via
The Motley Fool
How Did 2022’s Most Loved Stocks By Analysts Fare?
December 24, 2022
Via
Talk Markets
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
December 23, 2022
Via
Benzinga
Analyzing Horizon Therapeutics's Short Interest
December 22, 2022
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
December 22, 2022
Via
The Motley Fool
Interest Rate Hikes Won't Stop These 2 Cash-Rich Growth Stocks
December 21, 2022
Via
The Motley Fool
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
December 20, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.